Relmada Therapeutics, Inc. (RLMD)
Stock Price:
$37.39 USD
-1.37 (-3.53%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
568.26M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-22.99M |
| Shares Out |
15.20M |
| EPS (ttm) |
-1.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$37.39 |
| Previous Close |
$38.76 |
| Change ($) |
-1.37 |
| Change (%) |
-3.53% |
| Day's Open |
38.54 |
| Day's Range |
35.18 - 38.54 |
| Day's Volume |
126,916 |
| 52-Week Range |
35.18 - 54.00 |
More Stats
| Market Cap |
568.26M |
| Enterprise Value |
453.34M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
15.20M |
| Float |
7.51M |
| EPS (basic) |
-1.91 |
| EPS (diluted) |
-1.97 |
| FCF / Share |
-0.92 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.22M |
| Short Ratio |
7.33 |
| Short % of Float |
14.99% |
| Beta |
0.62 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.24 |
| Revenue |
n/a |
| Operating Income |
-22.38M |
| Net Income |
-22.99M |
| Free Cash Flow |
-13.51M |
| Net Cash |
114.92M |
| Net Cash / Share |
7.56 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-158.57% |
| ROE |
-25.63% |
| ROIC |
-52.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$67.83*
(81.41% upside)
Low
50.0
Current: $37.39
High
75.0
Target: 67.83
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -12.73 | -6.92 | -7.22 | -16.22 | -17.10 |
| Net Income | -17.32 | -8.96 | -6.29 | -2.97 | -20.80 |
| Shares Outstanding | 6.31 | 3.14 | 3.02 | 2.90 | 2.49 |
| Earnings Per Share | -2.74 | -2.86 | -2.08 | -1.04 | -8.36 |
| Operating Cash Flow | -10.50 | -6.00 | -6.47 | -13.14 | -16.23 |
| Capital Expenditures | - | -0.01 | -0.05 | -0.56 | -0.02 |
| Free Cash Flow | -10.50 | -6.01 | -6.52 | -13.71 | -16.25 |
| Cash & Equivalents | 9.22 | 2.24 | 1.71 | 8.50 | 22.47 |
| Total Debt | 0.36 | 2.94 | 0.28 | 0.27 | 0.26 |
| Net Cash / Debt | 8.85 | -0.70 | 1.43 | 8.23 | 22.21 |
| Assets | 10.22 | 3.05 | 2.84 | 10.24 | 24.39 |
| Liabilities | 2.61 | 8.56 | 1.38 | 3.20 | 15.58 |
| Book Value | 7.61 | -5.51 | 1.46 | 7.04 | 8.81 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Relmada Therapeutics, Inc. |
| Country |
United States |
| Employees |
6 |
| CEO |
Sergio Traversa |
Stock Information
| Ticker Symbol |
RLMD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: RLMD |
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, and proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.